Clinical trials: Antibody-mediated Rejection
Heart Transplant, Pediatric Heart Transplant
Non-invasive Prediction of EArly Cardiac rEjection
Acute rejection remains a major cause of morbidity and mortality in pediatric patients after heart transplant. In order to screen for rejection, most centers perform heart catheterizations with endomyocardial biopsies frequently…
- Conditions
- Heart Transplant, Pediatric Heart Transplant, Rejection, Cardiac MRI
- Trial name
- PEACE (NCT07770659)
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vanderbilt University Medical Center
Antibody-mediated Rejection, Kidney Transplant; Complications
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Antibody mediated rejection (ABMR) is a unique, significant and often severe form of allograft rejection. This single center, phase I/II, open label single-arm exploratory study focuses on enrolling ten patients with biopsy…
- Conditions
- Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form
- Trial name
- NCT03380377
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanley Jordan, MD
Kidney Failure, Chronic, End-Stage Renal Disease
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Patients who have had a previous allograft failure represent a major problem for transplant centers as they are highly-human leukocyte antigen (HLA) sensitized and unlikely to receive another transplant without significant…
- Conditions
- Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney
- Trial name
- NCT03380962
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanley Jordan, MD
Kidney Transplant Rejection
Using MSCs for Chronic Active Antibody Mediated Rejection
Mesenchymal stem cell (MSCs) therapy has already been studied in kidney transplant recipients (KTRs), and the available data showed that it is safe and well tolerated.
- Trial name
- NCT07005687
- Testing
- Stem Cells
- Volunteers
- 10 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Renal Transplant Rejection, Pediatric Kidney Disease
VIRTUUS Children's Study
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
- Conditions
- Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy
- Trial name
- VIRTUUS (NCT03719339)
- Where
- 13 sites in United States, Canada
- Volunteers
- 445 people
- Sponsor
- Children's Hospital of Philadelphia
Transplant Failure, Heart Transplant Rejection
MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)
Cross-sectional evaluation of antibody mediated injury in heart transplantation patients through a multimodal approach: electron microscopy, optic microscopy, immunohistochemistry techniques, transthoracic echocardiography…
- Conditions
- Transplant Failure, Heart Transplant Rejection, Antibody-mediated Rejection
- Trial name
- LEONE-HT (NCT05184426)
- Testing
- Echocardiogram, Cardiac magnetic resonance, Coronary angiography
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Juan Francisco Delgado Jimenez
Kidney; Complications, Allograft, Transplantation Infection
The Role of B Cells in Kidney Allograft Dysfunction
The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune response after kidney transplantation.
- Trial name
- NCT02294032
- Testing
- Immunosuppressive Agents
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Kidney Transplantation, Kidney Transplant Rejection
BAFF/APRIL in Kidney Transplant Rejection Risk Assessment
Antibody-mediated rejection (AMR) is a significant risk factor for graft loss in kidney transplantation. Soluble B cell-activating factor (sBAFF) and a proliferation-inducing ligand (APRIL) plays a critical role in the activation…
- Trial name
- BA-TRAP (NCT05779124)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Antibody-mediated Rejection
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
Chronic-active antibody-mediated rejection (cAMR) due to de novo or pre-formed donor specific antibody (DSA) is currently considered the main cause of long-term allograft losses.Based on the aim of reducing or eliminating DSA…
- Trial name
- NCT03737136
- Testing
- Bortezomib
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Cardiac Transplant Disorder, Cardiac Death
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Heart transplantation (HTx) is a procedure which is hindered by several complications. The HEARTS registry aims to allow the analysis of risk factors of all post-HTx complications.
- Conditions
- Cardiac Transplant Disorder, Cardiac Death, Heart Failure, Acute Cellular Graft Rejection
- Trial name
- HEARTS (NCT03393793)
- Volunteers
- 566 people
- Sponsor
- Lee S Nguyen
Antibody-mediated Rejection, NMO Spectrum Disorder
Biorepository and Registry for Plasma Exchange Patients
Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies.
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Trial name
- NCT05004493
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Charles M Knudson
Posttransplant Diabetes Mellitus, Acute Graft Rejection
Silymarin's Advantage on Graft Effectiveness
The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment.
- Conditions
- Posttransplant Diabetes Mellitus, Acute Graft Rejection, Biopsy Proven Acute Rejection, Antibody Mediated Rejection of Kidney Transplant
- Trial name
- SAGE (NCT06801886)
- Testing
- Silymarine supplementation
- Where
- Slovakia
- Volunteers
- 130 people
- Sponsor
- University Hospital, Martin
Transplant; Complication, Rejection
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant
The best treatment for kidney failure is a kidney transplant, but a transplanted kidney only works for about 10 to 15 years on average.
- Trial name
- MOT-AMR (NCT04496037)
- Testing
- Rituximab
- Volunteers
- 170 people
- Sponsor
- Imperial College London
Blood Disease, Platelet Refractoriness
HPA Antibodies and the Distribution of Antigen and Antibodies
By detecting platelet antibodies of participants and then further to identify their genotype and analyzing laboratory examination, the investigators will obtain positive frequency of HPA antibodies, the distribution of HPA…
- Conditions
- Blood Disease, Platelet Refractoriness, Antibody-mediated Rejection
- Trial name
- NCT03408158
- Testing
- same type infusion of main HPA antigen
- Where
- China
- Volunteers
- 6,170 people
- Sponsor
- Guangzhou First People's Hospital
Kidney Transplant Rejection, Antibody-mediated Rejection
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
This trial evaluates the addition of rituximab to standard of care in the treatment of antibody-mediated rejection in kidney transplant patients. The trial will involve adults and children.
- Trial name
- TAR:GET-1 (NCT03994783)
- Testing
- Rituximab, Methylprednisolone, Intravenous Immunoglobulin
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Liver Transplant Failure, Antibody-mediated Rejection
Antibodies and Liver Retransplantation
Despite reports that associate donor specific antibody (DSA) with rejection after liver transplantation, grafts are still allocated according to blood group (ABO) but not human leukocyte antigen (HLA) compatibility, possibly due…
- Trial name
- NCT03815864
- Testing
- Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
- Volunteers
- 200 people
- Sponsor
- London Health Sciences Centre